HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages

Macrophage infection by primate lentiviruses (HIV-1, HIV-2, and SIV) is restricted by, among other host factors, the MARCH1 membrane-associated protein. HIV-1 circumvents the MARCH1 restriction by using its accessory protein Vpu, which induces the anti-MARCH1 microRNAs 25 and 93. HIV-2 has infected up to 2 million people so far, and SIV infection is indispensable for animal models of primate lentivirus pathogenesis. These two lentiviruses do not have a <i>vpu</i> gene, but also target MARCH1 by inducing the same microRNAs. We have now determined that the HIV-2 and SIV antagonists of MARCH1 are their envelope glycoproteins. The HIV-2 and SIVmac239 Env glycoproteins upregulate microRNAs 25 and 93 by disrupting the β-catenin pathway, similar to HIV-1 Vpu. The fact that different lentiviruses have developed a similar strategy using microRNAs to counter MARCH1 antiviral activity emphasizes its relevance in the antiviral host response, as well as a target in antiviral therapy.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2025-11-24
DOI
https://doi.org/10.1128/jvi.01663-25
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages

Dorota Kmieć, Éric A. Cohen, Robert Lodge, Frank Kirchhoff
Journal of Virology
HIV Research and Treatment
article

HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages

Dorota Kmieć, Éric A. Cohen, Robert Lodge, Frank Kirchhoff
article en

Abstract

Macrophage infection by primate lentiviruses (HIV-1, HIV-2, and SIV) is restricted by, among other host factors, the MARCH1 membrane-associated protein. HIV-1 circumvents the MARCH1 restriction by using its accessory protein Vpu, which induces the anti-MARCH1 microRNAs 25 and 93. HIV-2 has infected up to 2 million people so far, and SIV infection is indispensable for animal models of primate lentivirus pathogenesis. These two lentiviruses do not have a <i>vpu</i> gene, but also target MARCH1 by inducing the same microRNAs. We have now determined that the HIV-2 and SIV antagonists of MARCH1 are their envelope glycoproteins. The HIV-2 and SIVmac239 Env glycoproteins upregulate microRNAs 25 and 93 by disrupting the β-catenin pathway, similar to HIV-1 Vpu. The fact that different lentiviruses have developed a similar strategy using microRNAs to counter MARCH1 antiviral activity emphasizes its relevance in the antiviral host response, as well as a target in antiviral therapy.

Journal of VirologyVol. 99(12)
Universität Ulm (DE), University Medical Center (US), Montreal Clinical Research Institute (CA), Université de Montréal (CA)
Openalex Percentile: Top 62%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages — Dorota Kmieć, Éric A. Cohen, et al. · Journal of Virology (2025) | TGRS Research Map | TGRS